Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone ...

Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025--In ...

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...
Nasdaq

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance

Kymera Therapeutics, Inc. KYMR announced that its investigational New Drug (IND) application for pipeline candidate, KT-621, has been cleared by the FDA. KT-621 is an investigational first-in-class ...
Healio

STAT5, STAT6 activate Th9 cells to drive allergic inflammation

Please provide your email address to receive an email when new articles are posted on . The STAT5 and STAT6 transcription factors activate Th9 cells. Th9 cells produce the IL-9 cytokine, which causes ...
BioWorld

Recludix Pharma gives update on STAT6 program

Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family involved in the regulation of immune response and inflammation. The development of SH2 domain inhibitors ...
Nasdaq

Nurix Therapeutics Secures $15 Million License Extension from Sanofi for STAT6 Program

Nurix Therapeutics secures a $15 million license extension from Sanofi for its STAT6 program, totaling $127 million to date. Nurix Therapeutics announced that Sanofi has exercised its option to ...
News Medical

Codiak's publication highlights the ability of exoASO-STAT6 to selectively target tumor-associated macrophages

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced the online publication of a ...
JSTOR Daily

STAT6 induces expression of Gas6 in macrophages to clear apoptotic neutrophils and resolve inflammation

Efferocytosis of apoptotic neutrophils (PMNs) by alveolar macrophages (AMΦs) is vital for resolution of inflammation and tissue injury. Here, we investigated the role of AMΦ polarization and ...
EurekAlert!

Data from Codiak’s exoASO™-STAT6 preclinical development program for the treatment of primary and metastatic hepatic cancers published in Science Advances

CAMBRIDGE, Mass., February 18, 2022 — Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of ...